### Dominican Republic

#### Population 2018

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>4.8 (3.7–6.1) 45 (35–57)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>1.2 (0.92–1.5) 11 (8.6–14)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.23 (0.11–0.38) 2.1 (1–3.6)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.25 (0.11–0.46) 2.4 (0.99–4.4)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.26 (0.19–0.34) 2.5 (1.8–3.2)</td>
</tr>
</tbody>
</table>

#### Tuberculosis profile

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>4.8 (3.7–6.1) 45 (35–57)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>1.2 (0.92–1.5) 11 (8.6–14)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.23 (0.11–0.38) 2.1 (1–3.6)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.25 (0.11–0.46) 2.4 (0.99–4.4)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.26 (0.19–0.34) 2.5 (1.8–3.2)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis 7%
- % with known HIV status 86%
- % pulmonary 90%
- % bacteriologically confirmed 60%
- % children aged 0-14 years 3%
- % women 34%
- % men 63%

Total cases notified 4 124

### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018 80% (63–100)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 11% (7–16)

### TB case notifications, 2018

- New cases 2.1% (0.69–4.3)
- Previously treated cases 34% (28–41)

TB/HIV care in new and relapse TB patients, 2018

- Number 833%
- % on antiretroviral therapy 61%

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance 22%
- New cases MDR/RR-TB: 100, XDR-TB: 2
- Previously treated cases MDR/RR-TB: 176, XDR-TB: 3

Laboratory-confirmed cases

- Patients started on treatment MDR/RR-TB: 82

#### Treatment success rate and cohort size

- New and relapse cases registered in 2017 74% 3 791
- Previously treated cases, excluding relapse, registered in 2017 40% 242
- HIV-positive TB cases registered in 2017 60% 841
- MDR/RR-TB cases started on second-line treatment in 2016 52% 107
- XDR-TB cases started on second-line treatment in 2016 100% 1

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment 28%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100%

#### TB financing, 2019

- National TB budget (US$ millions) 33
- Funding source: 57% domestic, 7% international, 36% unfunded

---

* Ranges represent uncertainty intervals
* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
* Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-19  Data: www.who.int/tb/data